OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Shah on Toxicites Associated With CAR T-Cell Therapy

November 10th 2017

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.

Dr. Melisko on the MA.17R Study for ER+ Breast Cancer

November 10th 2017

Michelle E. Melisko, MD, clinical professor of medicine, University of California, San Francisco (UCSF), discusses the MA.17R study for patients with breast cancer.

Dr. Alberts on Unmet Needs in CRC

November 10th 2017

Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses unmet needs facing patients with colorectal cancer (CRC).

Dr. Inman on Biomarkers for Immunotherapy in Bladder Cancer

November 10th 2017

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center discusses biomarkers for immunotherapy in patients with bladder cancer.

Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL

November 10th 2017

Jonathan Brammer, MD, hematologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma (CTCL).

Dr. Sabbatini on the Future of Dose-Dense Therapy in Ovarian Cancer

November 9th 2017

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the future of dose-dense therapy in ovarian cancer.

Dr. Larson on Ongoing Trials in Colorectal Cancer

November 9th 2017

Tim G. Larson, MD, oncologist, Minnesota Oncology, discusses ongoing trials in colorectal cancer (CRC).

Dr. Tolaney on the ATEMPT Trial for HER2+ Breast Cancer

November 9th 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the ATEMPT trial for patients with HER2-positive breast cancer.

Dr. Weber on the Toxicity Profile of Nivolumab Versus Ipilimumab for Melanoma

November 9th 2017

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the toxicity profile seen with nivolumab versus ipilimumab for patients with melanoma.

Dr. O'Neil on Left-Sided Versus Right-Sided CRC

November 9th 2017

Bert O'Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses left-sided versus right-sided colorectal cancer (CRC).

Dr. Ghamande Discusses GOG/NRG 0265 Study in Cervical Cancer

November 9th 2017

Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the GOG/NRG-0265 study in cervical cancer.

Dr. Feldman on Durvalumab for Patients With Lung Cancer

November 9th 2017

Lawrence E. Feldman, MD, medical oncologist, University of Illinois Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.

Dr. Majure on Unmet Needs for Patients With TNBC

November 8th 2017

Melanie C. Majure, MD, assistant clinical professor in the Division of Hematology/Oncology and breast oncologist, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses unmet needs for patients with triple-negative breast cancer (TNBC).

Dr. Mell on Risk Stratification for Head and Neck Cancer

November 8th 2017

Loren K. Mell, MD, assistant professor, Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, discusses risk stratification for patients with head and neck cancer.

Dr. Awan on the Importance of FISH Testing in CLL

November 8th 2017

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the importance of fluorescence in situ hybridization (FISH) testing for patients with chronic lymphocytic leukemia (CLL).

Dr. Leitao on the Role of Surgery in Ovarian Cancer

November 8th 2017

Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the role of surgery for patients with ovarian cancer.

Dr. Truty on Challenges With Treating Patients With Pancreatic Cancer

November 7th 2017

Mark J. Truty, MD, MS, assistant professor of surgery, Mayo Clinic, discusses challenges with treating patients with pancreatic cancer.

Dr. Simon on Durvalumab for Patients With Lung Cancer

November 7th 2017

George R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.

Dr. Zamarin on the Role of Pembrolizumab in Endometrial Cancer

November 7th 2017

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of pembrolizumab (Keytruda) for patients with endometrial cancer.

Dr. Hamlin on Key Points of a Study on Cerdulatinib in Non-Hodgkin Lymphoma

November 7th 2017

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a phase II study investigating cerdulatinib in patients with non-Hodgkin lymphoma.